Table 2.
Association between poliovirus type 2 seroprevalence and demographic factors and vaccination history, in individuals aged 6 months and older (n=375)
|
Seroprevalence |
Fisher's exact p value | |||
|---|---|---|---|---|
| n/N | % (95% CI) | |||
| Sex | .. | .. | 0·35 | |
| Male | 82/188 | 43·6% (36·4–51·0) | .. | |
| Female | 72/187 | 38·5% (31·5–45·9) | .. | |
| Age | .. | .. | 0·62 | |
| 6–11 months | 17/48 | 35·4% (22·2–50·5) | .. | |
| 12–36 months | 77/189 | 40·7% (33·7–48·1) | .. | |
| 36–59 months | 60/138 | 43·5% (35·1–52·2) | .. | |
| Number of nOPV2 doses reported | .. | .. | 0·39 | |
| 0 | 3/8 | 37·5% (8·5–75·5) | .. | |
| 1 | 7/25 | 28·0% (12·1–49·4) | .. | |
| 2 | 144/342 | 42·1% (36·8–47·5) | .. | |
| IPV dose reported | .. | .. | 0·58 | |
| No | 4/11 | 36·4% (10·9–69·2) | .. | |
| Yes | 102/237 | 43·0% (36·6–49·6) | .. | |
| Unknown | 48/127 | 37·8% (29·3–46·8) | .. | |
| Location (county) | .. | .. | 0·13 | |
| Bomi | 9/43 | 20·9% (10·0–36·0) | .. | |
| Bong | 17/40 | 42·5% (27·0–59·1) | .. | |
| Grand Bassa | 33/63 | 52·4% (39·4–65·1) | .. | |
| Grand Cape Mount | 3/7 | 42·9% (9·9–81·6) | .. | |
| Lofa | 6/18 | 33·3% (13·3–59·0) | .. | |
| Margibi | 10/23 | 43·5% (23·2–65·5) | .. | |
| Montserrado | 62/143 | 43·4% (35·0–51·2) | .. | |
| Nimba | 6/19 | 31·6% (12·6–56·6) | .. | |
| Rivercess | 8/19 | 42·1% (20·3–66·5) | .. | |
IPV=inactivated poliovirus vaccine. nOPV2=novel oral poliovirus vaccine type 2.